Literature DB >> 27521010

Mixed Anxiety and Depression : Diagnosis and Treatment Options.

D Bakish1,2,3, R Habib4,5, C L Hooper5,6.   

Abstract

Symptoms of anxiety and depression often appear together in patients, either as 2 discrete disorders, such as major depressive disorder and panic disorder, or as a combination of symptoms not meeting criteria for specific disorders. The social, economic, occupational and medical costs of such comorbid anxiety and depression can be enormous, affecting both the individual and society.The clinician must be creative when treating patients with mixed anxiety and depressive symptoms; psychopharmacological treatment can involve the use of a variety of mono- and polytherapies. Benzodiazepines can be effective in treating anxiety symptoms, but unwanted adverse effects limit their use to the short term. Tricyclic antidepressants, although proven to be effective in treating both anxiety and depressive symptoms, have numerous adverse effects, making them a second-choice therapy. Traditional monoamine oxidase inhibitors have proven efficacy in atypical depression, and the newer reversible and selective inhibitors of monoamine oxidase-A may prove to be very effective in treating both sets of symptoms. Of particular importance in the treatment of patients with anxiety and depressive symptoms are the selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors, nefazodone and the azapirones (including buspirone).

Entities:  

Year:  1998        PMID: 27521010     DOI: 10.2165/00023210-199809040-00003

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  56 in total

Review 1.  Pharmacological treatment of depression and comorbid anxiety disorders.

Authors:  G B Cassano; S Michelini
Journal:  Adv Biochem Psychopharmacol       Date:  1995

2.  The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group.

Authors:  A Khan; G V Upton; R L Rudolph; R Entsuah; S M Leventer
Journal:  J Clin Psychopharmacol       Date:  1998-02       Impact factor: 3.153

3.  [Sertraline in the treatment of mixed anxiety and depression disorder].

Authors:  J L Carrasco; M Díaz-Marsá; J Sáiz
Journal:  Actas Luso Esp Neurol Psiquiatr Cienc Afines       Date:  1997 May-Jun

4.  Recurrent brief depression: a new subtype of affective disorder.

Authors:  J Angst; K Merikangas; P Scheidegger; W Wicki
Journal:  J Affect Disord       Date:  1990-06       Impact factor: 4.839

5.  The prevalence of psychiatric disorders in a primary care practice.

Authors:  J E Barrett; J A Barrett; T E Oxman; P D Gerber
Journal:  Arch Gen Psychiatry       Date:  1988-12

6.  Response of anxiety and agitation symptoms during nefazodone treatment of major depression.

Authors:  J Fawcett; R N Marcus; S F Anton; K O'Brien; U Schwiderski
Journal:  J Clin Psychiatry       Date:  1995       Impact factor: 4.384

7.  A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group.

Authors:  S A Montgomery; A McIntyre; M Osterheider; P Sarteschi; W Zitterl; J Zohar; M Birkett; A J Wood
Journal:  Eur Neuropsychopharmacol       Date:  1993-06       Impact factor: 4.600

8.  A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients.

Authors:  J De Wilde; R Spiers; C Mertens; F Bartholomé; G Schotte; S Leyman
Journal:  Acta Psychiatr Scand       Date:  1993-02       Impact factor: 6.392

Review 9.  Mixed anxiety and depression: diagnostic issues.

Authors:  J P Boulenger; Y J Lavallée
Journal:  J Clin Psychiatry       Date:  1993-01       Impact factor: 4.384

10.  Emergence of depressive symptoms in patients receiving alprazolam for panic disorder.

Authors:  R B Lydiard; M T Laraia; J C Ballenger; E F Howell
Journal:  Am J Psychiatry       Date:  1987-05       Impact factor: 18.112

View more
  2 in total

Review 1.  Tianeptine: a review of its use in depressive disorders.

Authors:  A J Wagstaff; D Ormrod; C M Spencer
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Molecular dynamics of 5-HT1A and 5-HT2A serotonin receptors with methylated buspirone analogues.

Authors:  A Bronowska; Z Chilmonczyk; A Leś; O Edvardsen; R Ostensen; I Sylte
Journal:  J Comput Aided Mol Des       Date:  2001-11       Impact factor: 3.686

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.